{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:12:51Z","timestamp":1788793971678,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["182687\u20132016"],"award-info":[{"award-number":["182687\u20132016"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["198073"],"award-info":[{"award-number":["198073"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ygyno.2022.10.027","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T02:42:31Z","timestamp":1668134551000},"page":"39-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["The cost-effectiveness of opt-in and send-to-all HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: The Equalscreen randomized controlled trial"],"prefix":"10.1016","volume":"168","author":[{"given":"Tara","family":"Knauss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo T.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kine","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunvor","family":"Aasb\u00f8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Kunst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.ygyno.2022.10.027_bb0005","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1016\/j.ejca.2009.07.018","article-title":"Trends of cervical cancer mortality in the member states of the European Union","volume":"45","author":"Arbyn","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"15","key":"10.1016\/j.ygyno.2022.10.027_bb0010","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1016\/j.ejca.2013.04.024","article-title":"Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors","volume":"49","author":"Vaccarella","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2022.10.027_bb0015","series-title":"Cancer in Norway 2020 - Cancer Incidence, Mortality, Survival and Prevalence in Norway","author":"Norway CRo","year":"2021"},{"key":"10.1016\/j.ygyno.2022.10.027_bb0020","series-title":"Annual Rapport 2019, Screening Activity and Results from the National Cervical Cancer Screening Programme, [\u00c5rsrapport 2019, Screeningaktivitet Og Resultater Fra Livmorhalsprogrammet]","author":"Norway CRo","year":"2020"},{"issue":"9","key":"10.1016\/j.ygyno.2022.10.027_bb0025","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/jnci\/djn099","article-title":"Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden","volume":"100","author":"Andrae","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"issue":"6","key":"10.1016\/j.ygyno.2022.10.027_bb0030","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/eurpub\/ckx073","article-title":"Advancing the evaluation of cervical cancer screening: development and application of a longitudinal adherence metric","volume":"27","author":"Pedersen","year":"2017","journal-title":"Eur. J. Pub. Health"},{"key":"10.1016\/j.ygyno.2022.10.027_bb0035","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/s41416-022-01954-9","article-title":"HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: a pragmatic randomised controlled trial","volume":"127","author":"Aasb\u00f8","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2022.10.027_bb0040","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/sextrans-2016-052609","article-title":"The acceptability of self-sampled screening for HPV DNA: a systematic review and meta-analysis","volume":"93","author":"Nelson","year":"2017","journal-title":"Sex. Transm. Infect."},{"key":"10.1016\/j.ygyno.2022.10.027_bb0045","article-title":"Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses","volume":"363","author":"Arbyn","year":"2018","journal-title":"Bmj."},{"issue":"4","key":"10.1016\/j.ygyno.2022.10.027_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151978","article-title":"Self-sampling for human papillomavirus testing among non-attenders increases attendance to the Norwegian cervical Cancer screening Programme","volume":"11","author":"Enerly","year":"2016","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.ygyno.2022.10.027_bb0055","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1002\/ijc.28545","article-title":"Increasing participation in cervical cancer screening: offering a HPV self-test to long-term non-attendees as part of RACOMIP, a Swedish randomized controlled trial","volume":"134","author":"Broberg","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"16","key":"10.1016\/j.ygyno.2022.10.027_bb0060","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.ejca.2015.07.006","article-title":"Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: a systematic review and meta-analysis of randomised trials","volume":"51","author":"Verdoodt","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2022.10.027_bb0065","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/ijc.31391","article-title":"A randomized, controlled trial of two strategies of offering the home-based HPV self-sampling test to non- participants in the Flemish cervical cancer screening program","volume":"143","author":"Kellen","year":"2018","journal-title":"Int. J. Cancer"},{"issue":"11","key":"10.1016\/j.ygyno.2022.10.027_bb0070","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1002\/ijc.32374","article-title":"Increasing participation in cervical screening by targeting long-term nonattenders: randomized health services study","volume":"145","author":"Elfstr\u00f6m","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2022.10.027_bb0075","series-title":"Principles for Priority Setting in Health Care","author":"Services NMoHaC","year":"2017"},{"issue":"1","key":"10.1016\/j.ygyno.2022.10.027_bb0080","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1055-9965.EPI-16-0350","article-title":"The cost-effectiveness of cervical self-sampling to improve routine cervical cancer screening: the importance of respondent screening history and compliance","volume":"26","author":"Burger","year":"2017","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"11","key":"10.1016\/j.ygyno.2022.10.027_bb0085","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/bjc.2014.510","article-title":"Vaginal self-sampling is a cost-effective way to increase participation in a cervical cancer screening programme: a randomised trial","volume":"111","author":"Haguenoer","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2022.10.027_bb0090","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/ijc.33850","article-title":"Switching clinic-based cervical cancer screening programs to human papillomavirus self-sampling: a cost-effectiveness analysis of vaccinated and unvaccinated Norwegian women","volume":"150","author":"Pedersen","year":"2022","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2022.10.027_bb0095","first-page":"152","article-title":"CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials","author":"AD","year":"2010","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ygyno.2022.10.027_bb0100","series-title":"Nasjonalt handlingsprogram med retningslinjer for gynekologisk kreft","author":"Cancer NDoHNGoG","year":"2021"},{"key":"10.1016\/j.ygyno.2022.10.027_bb0105","series-title":"Guidelines for the Submission of Documentation for Single Technology Assessments (STAs) of Medical Devices and Diagnostic Interventions","author":"Health NIoP","year":"2021"},{"key":"10.1016\/j.ygyno.2022.10.027_bb0110","series-title":"Implementering av hjemmepr\u00f8vetaking \u00abhjemmetest\u00bb i Livmorhalsprogrammet","author":"Groeneveld","year":"2021"},{"key":"10.1016\/j.ygyno.2022.10.027_bb0115","author":"UK ER"},{"key":"10.1016\/j.ygyno.2022.10.027_bb0120","series-title":"CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations","author":"Husereau","year":"2022"},{"key":"10.1016\/j.ygyno.2022.10.027_bb0125","author":"Health NDo"},{"issue":"8","key":"10.1016\/j.ygyno.2022.10.027_bb0130","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.jval.2015.08.003","article-title":"Using decision-analytic modeling to isolate interventions that are feasible, efficient and optimal: an application from the Norwegian cervical cancer screening program","volume":"18","author":"Pedersen","year":"2015","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.ygyno.2022.10.027_bb0135","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12885-018-4165-4","article-title":"Preventing cervical cancer using HPV self-sampling: direct mailing of test-kits increases screening participation more than timely opt-in procedures - a randomized controlled trial","volume":"18","author":"Tranberg","year":"2018","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2022.10.027_bb0140","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2018-001351","article-title":"Self-sampling for human papillomavirus (HPV) testing: a systematic review and meta-analysis","volume":"4","author":"Yeh","year":"2019","journal-title":"BMJ Glob. Health"},{"issue":"12","key":"10.1016\/j.ygyno.2022.10.027_bb0145","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/j.ejca.2011.11.022","article-title":"Offering self-sampling for human papillomavirus testing to non-attendees of the cervical screening programme: characteristics of the responders","volume":"48","author":"G\u00f6k","year":"2012","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.ygyno.2022.10.027_bb0150","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/ijc.22484","article-title":"Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs","volume":"120","author":"Bais","year":"2007","journal-title":"Int. J. Cancer"},{"issue":"68","key":"10.1016\/j.ygyno.2022.10.027_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20680","article-title":"A cluster randomised trial of strategies to increase cervical screening uptake at first invitation (STRATEGIC)","volume":"20","author":"Kitchener","year":"2016","journal-title":"Health Technol. Assess."},{"issue":"2","key":"10.1016\/j.ygyno.2022.10.027_bb0160","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/0969141317704679","article-title":"Cost-effectiveness of strategies to increase cervical screening uptake at first invitation (STRATEGIC)","volume":"25","author":"Tsiachristas","year":"2018","journal-title":"J. Med. Screen."},{"issue":"1","key":"10.1016\/j.ygyno.2022.10.027_bb0165","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1186\/s12885-020-07085-9","article-title":"Cost-effectiveness analysis of repeated self-sampling for HPV testing in primary cervical screening: a randomized study","volume":"20","author":"Aarnio","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2022.10.027_bb0170","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12905-015-0261-7","article-title":"The costs of offering HPV-testing on self-taken samples to non-attendees of cervical screening in Finland","volume":"15","author":"Virtanen","year":"2015","journal-title":"BMC Womens Health"},{"issue":"5","key":"10.1016\/j.ygyno.2022.10.027_bb0175","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1158\/1055-9965.EPI-14-0998","article-title":"Offering self-sampling to non-attendees of organized primary HPV screening: when do harms outweigh the benefits?","volume":"24","author":"Rozemeijer","year":"2015","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"4","key":"10.1016\/j.ygyno.2022.10.027_bb0180","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/01.AOG.0000120143.50098.c7","article-title":"Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more","volume":"103","author":"Goldie","year":"2004","journal-title":"Obstet. Gynecol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582201914X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582201914X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:02:37Z","timestamp":1758772957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082582201914X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":36,"alternative-id":["S009082582201914X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.10.027","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cost-effectiveness of opt-in and send-to-all HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: The Equalscreen randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.10.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}